Should I buy or sell Quanterix stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QTRX shares. View QTRX analyst ratings or view top-rated stocks .

What is Quanterix's stock price target for 2024?

6 Wall Street research analysts have issued twelve-month target prices for Quanterix's shares. Their QTRX share price targets range from $30.00 to $34.00. On average, they expect the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 100.1% from the stock's current price. View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts .

How have QTRX shares performed in 2024?

Quanterix's stock was trading at $27.34 at the beginning of the year. Since then, QTRX shares have decreased by 41.5% and is now trading at $15.99. View the best growth stocks for 2024 here .

Are investors shorting Quanterix?

Quanterix saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 1,000,000 shares, a drop of 18.7% from the March 15th total of 1,230,000 shares. Based on an average daily volume of 334,600 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.9% of the company's shares are sold short. View Quanterix's Short Interest .

When is Quanterix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our QTRX earnings forecast .

How were Quanterix's earnings last quarter?

Quanterix Co. (NASDAQ:QTRX) posted its earnings results on Thursday, February, 29th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.05. The business earned $31.55 million during the quarter, compared to the consensus estimate of $27.92 million. Quanterix had a negative net margin of 26.42% and a negative trailing twelve-month return on equity of 9.15%.

What guidance has Quanterix issued on next quarter's earnings?

Quanterix issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $139.0 million-$144.0 million, compared to the consensus revenue estimate of $138.2 million.

What is Kevin Hrusovsky's approval rating as Quanterix's CEO?

15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com . Kevin Hrusovsky has an approval rating of 70% among the company's employees.

What other stocks do shareholders of Quanterix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT) , Novavax (NVAX) , Akoustis Technologies (AKTS) , Advanced Micro Devices (AMD) , CRISPR Therapeutics (CRSP) , Walt Disney (DIS) , Illumina (ILMN) , Sorrento Therapeutics (SRNE) , Cisco Systems (CSCO) and Intellia Therapeutics (NTLA) .

When did Quanterix IPO?

Quanterix (QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Who are Quanterix's major shareholders?

Quanterix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Amol Chaubal , David C Duffy, David C Duffy , David R Walt, Dawn Mattoon , E Kevin Hrusovsky , John J Fry, John J Fry , Laurie J Olson, Marijn E Dekkers , Mark T Roskey, Mark T Roskey , Masoud Toloue, Michael A Doyle and William P Donnelly. View institutional ownership trends .

How do I buy shares of Quanterix?

Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:QTRX

Quanterix (QTRX) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free QTRX Stock Alerts

$15.79

+0.04 (+0.25%)

(As of 04:35 PM ET)

Compare

Today's Range: $15.33
▼
$16.50
50-Day Range: $15.75
▼
$28.28
52-Week Range: $11.39
▼
$29.70

Volume: 357,790 shs
Average Volume: 346,044 shs
Market Capitalization: $603.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Get Quanterix alerts:

Quanterix MarketRank™ Stock Analysis

Analyst Rating: Buy
3.17 Rating Score
Upside/Downside: 100.1% Upside
$32.00 Price Target
Short Interest: Healthy
2.91% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.07
Based on 3 Articles This Week
Insider Trading: Selling Shares
$60,025 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.04) to ($1.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.14 out of 5 stars

Medical Sector

322nd out of 919 stocks

Analytical Instruments Industry

12th out of 26 stocks

3.6

Analyst's Opinion

Consensus Rating
Quanterix has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Quanterix has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.91% of the float of Quanterix has been sold short.
Short Interest Ratio / Days to Cover
Quanterix has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Quanterix has recently decreased by 18.70%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Quanterix does not currently pay a dividend.
Dividend Growth
Quanterix does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for QTRX.

3.4

News and Social Media Coverage

News Sentiment
Quanterix has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Quanterix this week, compared to 2 articles on an average week.
Search Interest
7 people have searched for QTRX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Quanterix to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quanterix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,025.00 in company stock.
Percentage Held by Insiders
Only 6.80% of the stock of Quanterix is held by insiders.
Percentage Held by Institutions
86.48% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Quanterix are expected to decrease in the coming year, from ($1.04) to ($1.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Quanterix is -18.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quanterix is -18.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Quanterix has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Quanterix Stock (NASDAQ:QTRX)

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.

QTRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QTRX Stock News Headlines

April 3, 2024 | insidertrades.com

Quanterix Co. (NASDAQ:QTRX) Director Laurie J. Olson Sells 1,000 Shares

April 16, 2024 | americanbankingnews.com

Quanterix Co. (NASDAQ:QTRX) Receives Average Recommendation of "Buy" from Brokerages

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 14, 2024 | americanbankingnews.com

Quanterix (NASDAQ:QTRX) Shares Down 7.5%

April 1, 2024 | finance.yahoo.com

Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain

March 27, 2024 | markets.businessinsider.com

Quanterix’s Strong IP Position Fuels Buy Rating in Alzheimer’s Diagnostic Market

March 26, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)

March 22, 2024 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 21, 2024 | finance.yahoo.com

Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure

March 21, 2024 | businesswire.com

Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure

March 16, 2024 | finance.yahoo.com

QTRX Apr 2024 22.500 call

March 16, 2024 | finance.yahoo.com

QTRX Apr 2024 27.500 put

March 11, 2024 | msn.com

CryoPort Q4 2023 Earnings Preview

March 7, 2024 | markets.businessinsider.com

Quanterix’s Growth Catalysts: FDA Breakthrough Designation and Alzheimer’s Diagnostic Potential

March 6, 2024 | stockhouse.com

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease

March 4, 2024 | realmoney.thestreet.com

Quanterix price target raised by $2 at Scotiabank, here's why

March 4, 2024 | finance.yahoo.com

Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease

March 3, 2024 | finance.yahoo.com

Quanterix Corporation (NASDAQ:QTRX) Just Released Its Annual Results And Analysts Are Updating Their Estimates

March 3, 2024 | finance.yahoo.com

Quanterix Corporation (NASDAQ:QTRX) Q4 2023 Earnings Call Transcript

March 2, 2024 | seekingalpha.com

Quanterix Corporation (QTRX) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

Quanterix Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

March 1, 2024 | markets.businessinsider.com

Quanterix: A Hold Rating Amidst Mixed Performance and Growth Potential

February 29, 2024 | finance.yahoo.com

Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023

February 29, 2024 | businesswire.com

Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023

February 28, 2024 | benzinga.com

Earnings Preview: Quanterix

February 27, 2024 | finance.yahoo.com

Quanterix Corp (QTRX) Aligns Earnings Release with Annual Report Filing, Reaffirms 2023 Guidance

See More Headlines

Receive QTRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Analytical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:QTRX
CUSIP: N/A
CIK: 1503274
Web: www.quanterix.com
Phone: (617) 301-9400
Fax: N/A
Employees: 441
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.00
High Stock Price Target: $34.00
Low Stock Price Target: $30.00
Potential Upside/Downside: +97.0%
Consensus Rating: Buy
Rating Score (0-4): 3.17
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.86)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,330,000.00
Net Margins: -26.42%
Pretax Margin: -25.84%
Return on Equity: -9.15%
Return on Assets: -7.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.84
Quick Ratio: 9.26

Sales & Book Value

Annual Sales: $122.37 million
Price / Sales: 5.08
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $9.17 per share
Price / Book: 1.77

Miscellaneous

Outstanding Shares: 38,250,000
Free Float: 35,476,000
Market Cap: $621.18 million
Optionable: Optionable
Beta: 1.30

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Dr. Masoud Toloue Ph.D. (Age 43)
President, CEO & Director
Comp: $957.03k
Dr. David R. Walt Ph.D. (Age 71)
Co-Founder, Chairman of Scientific Advisory Board & Independent Director
Comp: $47.25k
Dr. Mark T. Roskey Ph.D. (Age 64)
Senior Vice President of Strategic Partnerships
Comp: $495.03k
Mr. Michael A. Doyle (Age 68)
Executive Director of Finance
Comp: $570.14k
Ms. Vandana Sriram CPA (Age 50)
Chief Financial Officer
Mr. Daniel Pikora (Age 48)
Chief Operating Officer
Dr. David C. Duffy Ph.D. (Age 53)
Senior VP of Research & Development and CTO
Comp: $299.05k
Ms. Alexandra Phillips
Senior VP & Chief Information Officer
Ms. Laurie A. Churchill (Age 53)
Senior VP, General Counsel & Secretary
David Panzerella
Vice President of Sales

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

QTRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Quanterix stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last twelve months. There are currently 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QTRX shares.
View QTRX analyst ratings or view top-rated stocks.
What is Quanterix's stock price target for 2024?: 6 Wall Street research analysts have issued twelve-month target prices for Quanterix's shares. Their QTRX share price targets range from $30.00 to $34.00. On average, they expect the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 100.1% from the stock's current price.
View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts.
How have QTRX shares performed in 2024?: Quanterix's stock was trading at $27.34 at the beginning of the year. Since then, QTRX shares have decreased by 41.5% and is now trading at $15.99.
View the best growth stocks for 2024 here.
Are investors shorting Quanterix?: Quanterix saw a drop in short interest during the month of March. As of March 31st, there was short interest totaling 1,000,000 shares, a drop of 18.7% from the March 15th total of 1,230,000 shares. Based on an average daily volume of 334,600 shares, the days-to-cover ratio is currently 3.0 days. Currently, 2.9% of the company's shares are sold short.
View Quanterix's Short Interest.
When is Quanterix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our QTRX earnings forecast.
How were Quanterix's earnings last quarter?: Quanterix Co. (NASDAQ:QTRX) posted its earnings results on Thursday, February, 29th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.05. The business earned $31.55 million during the quarter, compared to the consensus estimate of $27.92 million. Quanterix had a negative net margin of 26.42% and a negative trailing twelve-month return on equity of 9.15%.

What guidance has Quanterix issued on next quarter's earnings?: Quanterix issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $139.0 million-$144.0 million, compared to the consensus revenue estimate of $138.2 million.
What is Kevin Hrusovsky's approval rating as Quanterix's CEO?: 15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees.
What other stocks do shareholders of Quanterix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA).
When did Quanterix IPO?: Quanterix (QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.
Who are Quanterix's major shareholders?: Quanterix's stock is owned by many different institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Laurie J Olson, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Masoud Toloue, Michael A Doyle and William P Donnelly.
View institutional ownership trends.
How do I buy shares of Quanterix?: Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QTRX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial